Journal of the American Veterinary Medical Association · 2022 · 11 citations · 18 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyComparative PharmacologyPharmacodynamicsLarge Animal PharmacologyPharmacodynamics Across SpeciesClot StabilityCoagulationProthrombin ActivationSelective Cyclooxygenase-2 InhibitorsViscoelastic EffectsViscoelastic Testing
OBJECTIVE: To evaluate the effect of the cyclooxygenase-2-selective NSAID firocoxib, compared to the nonselective NSAID flunixin meglumine on viscoelastic coagulation parameters in healthy horses. ANIMALS: 12 healthy adult mixed-breed horses. PROCEDURES: Following a crossover protocol, horses were administered flunixin meglumine (1.1 mg/kg, IV, q 12 h for 5 days), allowed a 6-month washout period, and then administered firocoxib (0.3 mg/kg, PO, once, then 0.1 mg/kg, PO, q 24 h for 4 days). Omeprazole (1 mg/kg, PO, q 24 h) was administered concurrently with each NSAID. Viscoelastic coagulation profiles and traditional coagulation parameters (prothrombin time, partial thromboplastin time, and fibrinogen) were measured before and after each treatment. RESULTS: Viscoelastic coagulation parameters were within reference intervals before and after both treatments. There was a statistically significant difference between treatments for amplitude at 10 minutes after clot time (P = .02) and maximum clot formation (P = .02); however, the magnitude of change was not clinically significant. CLINICAL RELEVANCE: Short-term administration of flunixin meglumine and firocoxib did not result in significant alteration of viscoelastic coagulation profiles in healthy horses. However, clinicians should be aware of possible coagulopathy secondary to NSAID administration with long-term use or critical illness, and further study is indicated.
18
Coxibs and Cardiovascular Disease
Garret A. FitzGerald · New England Journal of Medicine · 2004 · 896 citations
Failing the Public Health — Rofecoxib, Merck, and the FDA
Eric J. Topol · New England Journal of Medicine · 2004 · 598 citations · Full text
COX-2 is not involved in thromboxane biosynthesis by activated human platelets.
Paola Patrignani, Maria G. Sciulli, Stefano Manarini et al. · PubMed · 1999 · 115 citations
Medicine, Biochemistry, Pharmacology +15